ZS Genetics puts DNA under the microscope
ZS Genetics has signed up outside academic assistance to speed
up development of its 'revolutionary' microscopy-based genetic
analysis technology platform.
bioMerieux buys standards innovator BTF
Industrial microbiology expert bioMerieux has acquired Australian
firm BTF, strengthening its quality control (QC) and manufacturing
quality assurance (QA) offerings to the pharmaceutical industry.
J&J 'concerned' as Sandoz gets biosimilar EU approval
J&J has expressed its concern over patient safety as Novartis'
subsidiary Sandoz has received the green light from the European
Commission to launch the first epoetin alfa biosimilar on the EU
Dow extracts the stress from bioprocessing
US researchers have shown certain organic solvents can be used to
selectively extract therapeutic proteins from host bacteria,
avoiding the need for cell lysis and increasing product purity by a
factor of five.
New depth filter released
US-based Pall Corporation has launched a new depth filter which is
disposable and can be scalable from personalized medicine
applications to large scale commercial use.
Baxter recalls more infusion pumps
Baxter Healthcare remains in murky waters in regard to its infusion
pumps after announcing yesterday it would be recalling an
additional 986 of its Colleague brand pumps.
Panacos develops new class of fusion inhibitors
Panacos, a US based pharma firm, has outlined its work to identify
three new series of compounds that inhibit HIV fusion at a
different site to the only approved fusion inhibitor, Roche's
Study pushes conventional envelope on bioprocessing
The first study comparing traditional and optical sensors in cell
culture has been published and the authors are heralding it as a
potential paradigm shift in the realm of bioprocessing.
Sustainability study provides risk assessment
A new study by Deloitte Consulting has been developed to help
manufacturers assess the impact that the drive towards
sustainability could have on their business and operations.
Novo Nordisk gets transparent on bioethics
Biopharma company Novo Nordisk has launched a new website dedicated
to bioethics which it claims is the first of its kind in the
Anthera's first-in-class heart drug ahead of schedule
The mid-stage trial of a drug that tackles atherosclerosis in a
totally new way is months ahead of schedule, according to its
Procter & Gamble looking to outsource API work
Procter & Gamble (P&G) has announced its intention to
outsource the active pharmaceutical ingredient (API) R&D and
manufacturing work undertaken at one of its US factories, with
resultant closure of the site and job losses.
Updated FDA follow-on biologics bill released amidst anticipation and trepidation
A long-awaited and in some cases, long-feared, regulatory pathway
for the US Food and Drug Administration (FDA) approval of follow-on
biologics is now closer to fruition.
Three new 'biosimilars' to be launched in EU
A European regulatory committee has recommended the approval of
three generic versions of Johnson & Johnson's (J&J) anaemia
blockbuster Eprex in what could lead to the market launch of new
"biosimilars" by the...
Roche signs $370m deal for Phase I arthritis drug
Roche has committed hundreds of millions of dollars to an
early-phase rheumatoid arthritis drug, a move that is indicative of
big pharma's increasing tendency to license earlier phase